Quinoline, 3-[3-(4-bromophenyl)-1,2,4-oxadiazol-5-yl]-7-methoxy- manufacturers
- BT173
-
- $148.00 / 1mg
-
2025-11-09
- CAS:2232180-74-2
- Min. Order:
- Purity: 98.25%
- Supply Ability: 10g
|
| | Quinoline, 3-[3-(4-bromophenyl)-1,2,4-oxadiazol-5-yl]-7-methoxy- Basic information |
| | Quinoline, 3-[3-(4-bromophenyl)-1,2,4-oxadiazol-5-yl]-7-methoxy- Chemical Properties |
| Boiling point | 548.9±60.0 °C(Predicted) | | density | 1.488±0.06 g/cm3(Predicted) | | pka | 2.51±0.26(Predicted) | | form | Solid | | color | White to light yellow |
| | Quinoline, 3-[3-(4-bromophenyl)-1,2,4-oxadiazol-5-yl]-7-methoxy- Usage And Synthesis |
| Description | BT173 is a novel inhibitor of homeodomain interacting protein kinase 2 (HIPK2 ), attenuating renal fibrosis through suppression of the TGF-?1/Smad3 pathway. | | Uses | BT173 is a potent homeodomain interacting protein kinase 2 (HIPK2) inhibitor. BT173 binds to HIPK2 does not inhibit HIPK2 kinase activity but rather, interfered allosterically with the ability of HIPK2 to associate with Smad3. BT173 attenuates renal fibrosis through suppression of the TGF-β1/Smad3 pathway[1]. | | References | [1] Ruijie Liu, et al. A Novel Inhibitor of Homeodomain Interacting Protein Kinase 2 Mitigates Kidney Fibrosis through Inhibition of the TGF- β 1/Smad3 Pathway. J Am Soc Nephrol. 2017 Jul;28(7):2133-2143. DOI:10.1681/ASN.2016080841 |
| | Quinoline, 3-[3-(4-bromophenyl)-1,2,4-oxadiazol-5-yl]-7-methoxy- Preparation Products And Raw materials |
|